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Abstract
Background: Ischaemic heart disease (IHD) is a complex disease due to the combination of
environmental and genetic factors. Mutations in the MEF2A gene have recently been reported in
patients with IHD. In particular, a 21 base pair deletion (Δ7aa) in the MEF2A gene was identified in
a family with an autosomal dominant pattern of inheritance of IHD. We investigated this region of
the MEF2A gene using an Irish family-based study, where affected individuals had early-onset IHD.
Methods: A total of 1494 individuals from 580 families were included (800 discordant sib-pairs and
64 parent-child trios). The Δ7aa region of the MEF2A gene was investigated based on amplicon size.
Results: The Δ7aa mutation was not detected in any individual. Variation in the number of CAG
(glutamate) and CCG (proline) residues was detected in a nearby region. However, this was not
found to be associated with IHD.
Conclusion: The Δ7aa mutation was not detected in any individual within the study population
and is unlikely to play a significant role in the development of IHD in Ireland. Using family-based
tests of association the number of tri-nucleotide repeats in a nearby region of the MEF2A gene was
not associated with IHD in our study group.
Background
The search for novel polymorphisms that increase the
likelihood of IHD has recently led to the discovery of a
potentially important role of the myocyte enhancing fac-
tor 2A gene (MEF2A). In 2003, Wang and colleagues [1]
reported that they had identified a 21 base pair (bp) dele-
tion (Δ7aa) of the MEF2A gene in a family with IHD,
where the disease appeared to have an autosomal domi-
nant pattern of inheritance. Subsequent investigation by
the same research group revealed 3 further mutations in a
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separate part of the MEF2A gene. These authors suggest
that mutations in the MEF2A gene may play a substantial
role in the development of IHD.
Attempts to confirm this association to date have not been
successful in case-control studies in both a Canadian [3]
and, more recently, a Japanese population [4]. We sought
to investigate the role of the Δ7aa mutation in a large fam-




Recruitment of the study population took place between
August 1999 and October 2004. The inclusion criteria are
described in detail in a previous publication [5]. Briefly,
individuals were Caucasian with all four grandparents
born in Ireland. Each family was required to have at least
one family member affected with proven premature IHD
(disease onset ≤ 55 years for males and ≤ 60 years for
females) and at least one unaffected sibling and/or both
parents surviving. Proven IHD was defined by one or
more of the following: previous myocardial infarction
(MI), previous unstable angina (typical chest pain with
dynamic ECG changes or minor elevation of cardiac
markers) or stable angina with angiographic evidence of
obstructive coronary disease (>70% stenosis). Unaffected
siblings were required to be 3 years older than the affected
sibling at age of diagnosis of IHD and have no evidence of
previous IHD using the "Rose chest pain on effort and
possible infarction questionnaire" [6] and a standard 12
lead electrocardiogram independently coded using the
"Minnesota code" [7].
Written informed consent was obtained from each
patient. The study was approved by the Research Ethics
Committee of Queen's University Belfast and the investi-
gation conforms to the principles outlined in the Declara-
tion of Helsinki.
Statistical analysis
Two family based tests of association were used to analyse
the data: the combined transmission disequilibrium test
(TDT)/sib-TDT and the pedigree disequilibrium test
(PDT) [8,9]. These tests avoid the problem of population
stratification that is found in case-control studies.
Genotyping
Polymerase chain reaction (PCR) amplification of the
Δ7aa region was undertaken, using a fluorescently
labelled primer (MWG Biotech Ebersberg, Germany). The
PCR conditions were as previously described [5]. The for-
ward primer sequence was GCATCAAGTCCGAACCGATT
and the reverse primer sequence was GGAGCGACCCATT-
TCCTGTC. Amplification products were run on a capillary
ABI PRISM® 3100 Genetic Analyser with a commercially
available size standard (ROX 400™, Applied Biosystems).
Sequencing of a random sample of 10 individuals was
performed on a capillary ABI PRISM® 3100 Genetic Ana-
lyser. Results were analysed by Sequencher™ (Gene Codes
Corporation, Michigan, USA).
Results
The risk factors for both probands and siblings are shown
below in Table 1. Of note, there are more male probands,
and more female siblings, this reflects the earlier onset of
IHD in men compared with women. Smoking and diabe-
tes are more common in the probands. However, hyper-
tension and elevated levels of lipoproteins were less
Table 1: Risk factors in probands and their siblings with premature onset IHD.
Risk factor Probands Siblings
Age 52.0 56.0
Female 113 (19.5%) 429 (54.6%)
Male 467 (80.5%) 357 (45.4%)
Body mass index 28.5 28.2
Non smoker 116 (20.0%) 328 (41.7%)
Ex smoker (≥ 1 year) 249 (42.9%) 224 (28.5%)
Current smoker 215 (37.1%) 235 (29.9%)
Hypertension treatment 148 (25.5%) 177 (22.5%)
Systolic BP ≥ 140 mmHg 30 (5.2%) 239 (30.4%)
Diastolic BP ≥ 95 mmHg 1 (0.2%) 2 (0.3%)
Total hypertension 179 (30.9%) 418 (53.2%)
Known diabetes 53 (9.1%) 43 (5.5%)
Random blood sugar ≥ 11.1 mmol/l 2 (0.3%) 6 (0.7%)
Total cholesterol (mmol/l) 4.9 5.8
Low density lipoprotein (mmol/l) 2.9 3.4
Triglycerides (mmol/l) 2.4 2.3
High density lipoprotein (mmol/l) 1.3 1.2BMC Medical Genetics 2006, 7:65 http://www.biomedcentral.com/1471-2350/7/65
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common in the probands probably reflecting the use of
vasoactive drugs to reduce blood pressure and the wide-
spread use of lipid lowering agents in this population.
A total of 1494 individuals from 580 families were
included (803 discordant sib-pairs and 64 parent-child
trios). Due to incomplete genotyping 13 individuals from
7 families were removed, leaving 1481 individuals from
573 families. Analysis was based on amplicon size of the
Δ7aa region of the MEF2A gene.
The Δ7aa mutation was not found in any individual in the
study sample. Differences in amplicon size were identified
and were due to variation in the numbers of triplet repeats
in a nearby region coding for glutamate or proline resi-
dues, as previously reported [3]. Using the TDT/sib-TDT
and PDT (352 informative families), the number of triplet
repeats was not found to be associated with disease in our
study group (Table 2).
Discussion
Although the majority of researchers working in the field
of complex traits propose a common-variant, small-effect
model, the possibility also exists of a rare- variant, large-
effect model. Wang and colleagues [1] reported the Δ7aa
mutation in a family of 13 patients who exhibited an
autosomal dominant inheritance pattern of IHD. Subse-
quent work by the same group [2] was undertaken in 207
unrelated patients, with a diagnosis of IHD based on ang-
iography or development of MI, and 191 control subjects.
Three novel mutations in exon 7 were found in four
patients and in none of their control subjects. However,
other groups have not confirmed this work. Weng and co-
workers [3] did identify the Δ7aa mutation in 3 individu-
als without evidence of IHD and further work within their
families did not show any evidence for cosegregation of
the mutation with early onset IHD. Similarly, Kajimoto
and colleagues, in a Japanese population, screened the
MEF2A gene in 379 patients with MI and 589 control indi-
viduals. They identified one nonsense mutation (R447X)
but were uncertain regarding the significance of this find-
ing, as the patient was elderly and had other conventional
risk factors for ischaemic heart disease. Research per-
formed by other groups have also identified similar varia-
tions in the number of glutamate residues, they to have
not found this to be associated with IHD; however, other
mutations may be [10].
Conclusion
Our research suggests that the Δ7aa mutation of the
MEF2A gene is unlikely to play a significant role in the
development of IHD in the Irish population. In addition,
statistical analysis using family-based methods suggests
that the triplet repeat polymorphism in this gene is not
associated with IHD in our study group.
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